Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells

Chinese Medical Journal

Volumn 123, Issue 23, 2010, Pages 3417-3421

  Lü, Yun ^a   Liu, Jing Hua ^a   Zhang, Li Ke ^b   Du, Jie ^a   Zeng, Xiang Jun ^b   Hao, Gang ^b   Huang, Ji ^a   Zhao, Dong Hui ^a   Wang, Guo Zhong ^a   Zhang, Ying Chuan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Endothelial dysfunction; Fibroblast growth factor 21; Oxidized low density lipoprotein

Indexed keywords

BEZAFIBRATE; FIBROBLAST GROWTH FACTOR 21; OXIDIZED LOW DENSITY LIPOPROTEIN; SHORT HAIRPIN RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; BEZAFIBRATE; CELLS, CULTURED; CORONARY ARTERY DISEASE; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTORS; LIPOPROTEINS, LDL; MALE; PPAR ALPHA; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 78649883767     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.23.008     Document Type: Article

References (15)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492: 203-206.
2. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Letters 2008; 582: 3805-3810.
3. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 14: 6018-6027.
4. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259.
5. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781.
6. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253.
7. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Kster A, Sandusky GE, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55: 2470-2478.
8. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 65-68.
9. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, et al. Different roles of N- and C-termini in the functional activity of FGF21. J Cell Physiol 2009; 219: 227-234.
10. Nishida M, Carley WW, Gerritsen ME, Ellingsen O, Kelly RA, Smith TW. Isolation and characterization of human and rat cardiac microvascular endothelial cells. Am J Physiol 1993; 264: 639-652.
11. Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, et al. PPAR alpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007; 360: 437-440.
12. Galman C, Lundason T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPAR alpha activation in man. Cell Metab 2008; 8: 169-174.
13. Wang H, Qiang L, Farmer SR. Identification of a domain within PPARgamma regulating expression of a group of genes containing FGF21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008; 28: 188-200.
14. Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen TS, Severson DL, et al. Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res 2009; 83: 519-526.
15. Chen HH, Chen TW, Lin H. Prostacyclin induced PPARr-alpha translocation attenuates NF-kappaB and TNF-alpha activation after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009; 297: 1109-1118.